Results of Public Offering
On October 10, 2007, EpiCept announced the pricing of a public offering of approximately 4.26 million shares of common stock at $1.88 per share and five- year warrants to purchase up to approximately 2.13 million shares of common stock at an exercise price of $1.88 per share. EpiCept received approximately $7.3 million in net proceeds from the offering. The warrants will become exercisable beginning six months after the closing. Shares outstanding at September 30, 2007 amounted to 37,952,289, and after the private placement increased to 42,210,758.
EpiCept will host a conference call to discuss third quarter 2007 results and provide a business update on Wednesday, November 7, 2007 at 8:30 a.m. EST. To participate in the live call, please dial (888) 802-7346 from the U.S. or Canada or (973) 582-2785 from international locations (please reference access code 9431155). The conference call will also be broadcast live on the Internet and may be accessed at http://www.epicept.com. The webcast will be archived for 90 days.
A telephone replay of the call will be available for seven days by dialing (877) 519-4471 from the U.S. and Canada or (973) 341-3080 from international locations (please reference reservation number 9431155).
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer.
EpiCept has a staged portfolio of pharmaceutical product candidates with
several pain therapies in late-stage clinical trials, and a lead oncology
compound for AML with demonstrated efficacy in a Phase III trial; a
marketing authorization application for this compound has been submitted in
Europe. EpiCept is headquartered in Tarrytown, N.Y. Its research and
development team in San Diego is pursuing a drug discovery progra
|SOURCE EpiCept Corporation|
Copyright©2007 PR Newswire.
All rights reserved